effective analysis of biomedical BIG DATA the optimization of drugs for rare and

neurodegenerative diseases, and cancer

FINISTERRAE

FINISTERRAE Big Data for the

optimization of drugs for rare and neurodegenerative

diseases, and Cancer.

“This generation has a historic opportunity and responsibility to transform medicine by

using systematic approaches in the biological sciences to dramatically accelerate the understanding and

treatment of disease” The Eli and Edythe L. Broad Institute

Of MIT and Harvard

FINISTERRAE means “the end of the

world”. In our case, it is referred to genomic and

biomedical BIG DATA principles with

translational means. Our goal is to make big data

smaller, completely reducing its complex

nature.

... making it easier to find new

therapeutic targets and orphan drugs for RARE DISEASES.

...and also in neurodegenerative

diseases (Parkinson,

Alzheimer, ALS,...) and Cancer.

What’s more, we want to make early diagnosis of various types of CANCER more accurate, as well as make the optimization of personalized treatment possible (precision translational medicine)

Also, the FINISTERRAE platform will

contribute to the OPTIMIZATION OF

MEDICAL DECISIONS and the providing

additional value to

hospital data.

Regarding drug optimization, SECONDARY EFFECTS MINIMIZATION would be very interesting so that patients do not have to go through unnecessary suffering.

LET’S TALK NUMBERS

7000: number of RARE DISEASES that affect over 30 million people in the USA and some more in Europe. Over the past

few years, small pharmaceutical companies have

launched various dozens of drugs.

NEURODEGENERATIVE DISEASES are one of the biggest issues of today’s

society. By itself, Alzheimer affects more

than 7 million Europeans, and it is thought that this

number will be duplicated in less than

20 years.

Despite all the billions of dollars invested in

CANCER investigation, the obtained results for

preventing it and for carrying out advanced treatments are highly

disappointing.

Only 500 out of 10.000 drugs found in

investigation period pass on to preclinical

period, and from there only 1 of them goes on

to clinical use. www.acrohealth.org

BREAST CANCER

MAMMAPRINT ONCOTYPE

MAMMOSTRAT are really expensive,

although trustworthy tests

possible metastasis prediction during

diagnosis

The goal is to come up with simple, solid, trustworthy and non-expensive methods to ameliorate diagnosis and Breast Cancer treatment, significantly reducing mortality.

And this methodology can also be applied to

other types of CANCER:

COLORECTAL, LUNG,

PROSTATE, PANCREAS…

We model biomedical data and we obtain information

that would be impossible to find using traditional

methods. We are opened for proofs of concepts to show

our capabilities.

We work using a win-win methodology.

S O M E F I N I S T E R R A E ’ S

R E F E R E N C E S

S O M E F I N I S T E R R A E ’ S

R E S U LT S

CORRELATION NETWORK for

CHRONIC LYMPHOCITIC LEUKEMIA (CLL)

Main Mutations in CLL and how they impact expression

CORRELATION NETWORK for MYOSITIS

CORRELATION NETWORK for ALS

• We have found very innovative results about the disease

mechanisms in Alzheimer, Parkinson, ALS and Multiple

Sclerosis, for instance. • We are modelling different rare

diseases that have genetic data available in public data

repositories. • We are able to fusion different

kind of data for Treatment Optimization.

Ignacio Fdez.-Alberti IIRR and Corporate Communications

Juan Luis Fdez.-Martínez

Professor in Applied Mathematics.

CTO.

Zulima Fernández-Muñiz

PhD in Applied Mathematics.

Ana Cernea-Cobernau PhD in Applied Mathematics.

Enrique J. De Andrés Galiana

PhD in Applied Mathematics.

The TEAM

Juan Luis Fernández Martínez

Inverse Problems Group jlfm@uniovi.es

+34 682202198

Ignacio Fdez. Alberti Salud Social Media

ignacioalberti@saludsocialmedia.com

CONTACT TO DISCOVER NEW OPPORTUNITIES